Pharmedic (PMC) to Pay 1,964 VND Dividend on Sept 9, 2025 Yield 43.64%
This Aveluro analysis covers PMC (Pharmedic) on HNX in the Health Care sector. The classified event type is dividend announcement, with positive sentiment and a deterministic market-impact score of 5.6/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Pharmedic (PMC), listed on HNX, will pay a third cash dividend for 2025 of 1,964 VND per share on September 9, 2026, bringing total 2025 cash dividends to 43.64% (4,364 VND/share). The company has a history of high cash dividends, though 2026 first-half profit fell 19.34%.
Key Facts
- Record date: August 25, 2026; payment date: September 9, 2026.
- Third dividend: 1,964 VND/share (19.64% of par value).
- Total 2025 cash dividend: 4,364 VND/share (43.64% of par value).
- Estimated payout for this round: ~18.3 billion VND (9.3 million shares outstanding).
- 2023 total cash dividend: 19,100 VND/share (191% of par value).
- 2024 total cash dividend: 17,168 VND/share (171.68% of par value).
- 2025 revenue: ~552 billion VND (+8% YoY); net profit: >82 billion VND.
- H1 2026 revenue: 257.67 billion VND (flat YoY); net profit: 36.35 billion VND (-19.34% YoY).
What Happened
Pharmedic (PMC) announced a third cash dividend for fiscal year 2025, paying 1,964 VND per share to shareholders on record as of August 25, 2026. The payment is scheduled for September 9, 2026. This follows earlier payments of 1,000 VND and 1,400 VND per share, bringing the total 2025 cash dividend to 4,364 VND per share, equivalent to 43.64% of par value.
The company, formerly known as PHARIMEX, has a long history of generous cash dividends. In 2023, it paid 19,100 VND per share (191% of par value) across five installments, and in 2024, it paid 17,168 VND per share (171.68% of par value). These payouts are supported by relatively stable earnings, with 2025 revenue of ~552 billion VND and net profit above 82 billion VND. However, in the first half of 2026, net profit declined 19.34% to 36.35 billion VND, signaling a slowdown.
Market Context
Pharmedic (PMC) trades on HNX, with a recent close of 130,000 VND on August 13, 2026. The stock’s high dividend yield (43.64% for 2025) is a key attraction for income-focused investors. The company’s payout ratio has historically been high, often exceeding 100% of earnings, funded by strong cash flow. The recent profit decline in H1 2026 may raise questions about sustainability, but the company’s track record suggests a commitment to maintaining shareholder returns.
Strategic Significance
For long-term investors, Pharmedic’s dividend policy is a core part of its investment thesis. The company has consistently returned cash to shareholders, even during periods of slower growth. However, the 19.34% drop in H1 2026 net profit could pressure future payouts if the trend continues. Investors should monitor whether the company can maintain its dividend levels while navigating the current slowdown. The pharmaceutical sector in Vietnam remains resilient, but competitive pressures and regulatory changes could impact margins.
What to Watch
- Q3 2026 earnings report (expected October 2026) to see if profit decline persists.
- Any guidance on 2026 dividend policy from management.
- Changes in pharmaceutical regulations or pricing policies.
- Cash flow and working capital trends to assess dividend sustainability.
- Share price reaction around the ex-dividend date (August 25, 2026).